Skip to main content

Table 3 Adverse reactions under RIT (all patients)

From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience

°III allergic reaction leading to discontinuation of cetuximab 4 pts (5,6%)
Skin reactions leading to cetuximab breaks 1 pt (1,4%)
Skin reactions leading to discontinuation of cetuximab 3 pts (4,2%)
Overall °III skin reactions 6 pts (8,3%)
Discontinuation of treatment due to detoriation of overall condition 5 pts (6,9%)